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Paclitaxel and capecitabine, which have distinct mechanisms of action and toxicity profiles, have each shown high activity as single
agents in gastric cancer. Synergistic interaction between these two drugs was suggested by taxane-induced upregulation of thymidine
phosphorylase. We, therefore, evaluated the antitumour activity and toxicities of paclitaxel and capecitabine as first-line therapy in
patients with advanced gastric cancer (AGC). Patients with histologically confirmed unresectable or metastatic AGC were treated
with capecitabine 825mgm
 2 p.o. twice daily on days 1–14 and paclitaxel 175mgm
 2 i.v. on day 1 every 3 weeks until disease
progression or unacceptable toxicities. Between June 2002 and May 2004, 45 patients, of median age 57 years (range¼38–73
years), were treated with the combination of capecitabine and paclitaxel. After a median 6 cycles (range¼1–9 cycles) of
chemotherapy, 43 were evaluable for toxicity and response. A total of 2 patients showed complete response and 20 showed partial
response making the overall response rate 48.9% (95% CI¼30.3–63.5%). After a median follow-up of 42.2 months (range¼31.2–
54.3 months), median time to progression was 5.6 months (95% CI¼3.9–7.2 months) and median overall survival was 11.3 months
(95% CI¼8.1–14.4 months). Grade 3 or 4 adverse events include neutropaenia (46.5% of patients), hand–foot syndrome (9.3%),
arthralgia (9.3%), and asthenia (4.7%). There was no neutropaenic fever or treatment-related deaths. Paclitaxel and capecitabine
combination chemotherapy was active and highly tolerable as a first-line therapy for AGC.
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Although the overall incidence of gastric cancer has steadily
declined in many Western countries during the last few decades
(Jemal et al, 2002), it is still the most common tumour in Korea
(Bae et al, 2002). Gastric cancer is often diagnosed at a very
advanced stage, with approximately half of all patients presenting
with unresectable, locally advanced, or metastatic disease. For
patients with advanced gastric cancer (AGC), the median survival
is only 6–10 months, and 5-year survival rates are o10%.
Four randomised studies comparing best-supportive care with
best-supportive care plus chemotherapy for AGC have shown that
chemotherapy can improve survival and quality of life (Murad
et al, 1993; Pyrhonen et al, 1995; Schipper and Wagener, 1996;
Glimelius et al, 1997). The combination of 5-FU plus cisplatin (FP)
resulted in improved response rates compared with 5-FU,
doxorubicin and mitomycin (FAM) or 5-FU single-agent therapy
(Kim et al, 1993), and showed a trend towards improved response
rates when compared with 5-FU, doxorubicin and methotrexate
(FAMTX) or etoposide, leucovorin and bolus 5-FU (ELF)
(Vanhoefer et al, 2000). The combination of epirubicin, cisplatin,
and infusional 5-FU (ECF) led to longer survival than the
combination of 5-FU, doxorubicin, and high-dose methotrexate
(FAMTX) (median overall survival (OS) 8.9 months vs 5.8 months)
(Webb et al, 1997). Thereafter, these two FP-based chemotherapy
regimens (FP and ECF) became a standard reference regimen in
first-line treatment for AGC. Nonetheless, the treatment outcomes
with these regimens were not satisfactory either in efficacy or
safety, such as inconvenience and complication associated with
portable pump for administration of infusional 5-FU, and nausea/
vomiting and neurotoxicity related with cisplatin. So, development
of more effective or better tolerable chemotherapy regimens have
been an urgent task in AGC.
Paclitaxel (Taxol
s; Bristol–Meyers Squibb Company, Prince-
ton, NJ, USA), the prototype taxane compound that interferes with
tubulin assembly (Rowinsky et al, 1990), has been studied
extensively in patients with previously treated or untreated gastric
cancer. As a single agent, paclitaxel induced responses in 11–17%
of previously untreated patients (Ajani et al, 1998; Garcia et al,
2001), and activity was also seen in previously treated patients
(Cascinu et al, 1998; Yamada et al, 2001). The in vitro cytotoxic
effects of paclitaxel plus 5-FU were found to depend on the
schedule used, in that application of paclitaxel before 5-FU
enhanced cytotoxicity, whereas the application of paclitaxel after
5-FU resulted in a less than additive cytotoxic effect (Kano et al,
1996). In patients with AGC, the combination of these two drugs
had response rates between 13 and 65.5%, with a rather low-
toxicity profile (Cascinu et al, 1997; Murad et al, 1999).
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s; Hoffmann-La Roche Ltd, Basel, Switzerland) is a 5-FU
prodrug developed to reduce the toxicity and enhance the
intratumour concentrations of 5-FU. Capecitabine is absorbed as
an intact molecule from the small bowel mucosa and converted
sequentially to 5-FU in a multistep enzymatic process (Bollag and
Hartmann, 1980; Hartmann and Bollag, 1980). In the first step,
capecitabine is metabolised by hepatic carboxyl esterase to 50-
deoxy-5-fluorocytidine (50-DFCR). This intermediate is metabo-
lised by cytidine deaminase to doxifluridine (50-DFUR) in hepatic
and extrahepatic tissues, including malignant tumours. Finally, 50-
DFUR is converted to 5-FU by the pyrimidine nucleoside
phosphorylase thymidine phosphorylase (dThdPase), a potent
tumour-associated angiogenesis factor preferentially expressed in
malignant cells (Ishikawa et al, 1998a). In preclinical xenograft
models, capecitabine was highly active against several tumours,
including breast, colorectal, gastric, and cervical tumours (Ishika-
wa et al, 1998b; Ishitsuka, 2000), and against both 5-FU-sensitive
and 5-FU-resistant tumours (Cao et al, 1997). Intermittent
capecitabine (1250mgm
 2 daily dose for 14 days, followed by a
7-day rest period) was shown to be active as a single agent in
previously untreated AGC patients, with a response rate of 28.2%
in 39 patients (Hong et al, 2004). Moreover, the combination of
capecitabine with other drugs, such as cisplatin, oxaliplatin,
epirubicin, and docetaxel, had an objective response rate of 40–
68% as first-line treatment in patients with AGC (Kim et al, 2002;
Kang et al, 2004; Park et al, 2004, 2006; Cho et al, 2005).
In human colon cancer xenograft model, thymidine phosphor-
ylase is upregulated and synergy between paclitaxel and capeci-
tabine has been observed (Sawada et al, 1998). The activity of
capecitabine in patients with breast cancer refractory to paclitaxel
and anthracyclines suggests that the combination of capecitabine
and paclitaxel may be effective in treating patients with advanced
breast cancer (Blum et al, 1999). Doses recommended are
capecitabine 1650mgm
 2 per day orally for 14 days and paclitaxel
175mgm
 2 i.v. every 3 weeks (Villalona-Calero et al, 2001).
We, therefore, performed a phase II study to evaluate the
antitumour activity and toxicities of the combination of paclitaxel
and capecitabine as first-line therapy in patients with AGC.
PATIENTS AND METHODS
Patient selection
Patients with histologically confirmed AGC, with at least one
measurable lesion of longest diameter X2cm, were considered
eligible for this study. In addition, patients 18–75 years old with
ECOG performance status of 0–2 and adequate liver, renal, and
bone marrow functions were eligible. Prior chemotherapy for
advanced disease was not permitted, but adjuvant chemotherapy
was allowed, providing it was completed at least 6 months before
the start of study treatment. Patients were excluded if they had
been previously exposed to taxane although fluoropyrimidine was
allowed as adjuvant therapy. Patients with unresolved bowel
obstruction or malabsorption syndrome were excluded. The
protocol was approved by the Institutional Review Board of the
Asan Medical Center, and all patients provided written informed
consent before enrollment.
Treatment schedule
Treatment consisted of i.v. paclitaxel 175mgm
 2 (diluted in
500ml of 0.9% sodium chloride solution) for 3h on day 1, followed
by oral capecitabine 825mgm
 2 twice daily from the evening of
day 1 to the morning of day 15, followed by a 7-day treatment-free
interval, in each 3-week cycle (Villalona-Calero et al, 2001).
Patients received standard i.v. hypersensitivity prophylaxis,
including dexamethasone 20mg, diphenhydramine 50mg, and
ranitidine 50mg, 30min before administration of paclitaxel.
Patients with response or stable disease received a maximum of
9 cycles of chemotherapy, or until disease progression, unaccep-
table toxicity, or refusal by the patient. Patients withdrawing from
the study due to adverse effects of study drugs could continue on
monotherapy.
Dose modification for adverse events
Toxicity was evaluated before each treatment cycle according to
the National Cancer Institute Common Toxicity Criteria (NCI
CTC), version 2.0. To begin the next treatment cycle, each patient
was required to have a platelet count X100 10
9l
 1, an absolute
neutrophil count X1.5 10
9l
 1 and resolution or improvement of
clinically significant non-haematological adverse events, except
alopecia, to grade 1 or 0. A treatment delay of up to 1 week was
permitted without dose reduction.
Treatment was continued at the same dose, without interruption
or dose reduction, in patients experiencing grade 1 or other
toxicities considered unlikely to become serious or life threatening
(e.g., alopecia). For all other treatment-related adverse events of
grade 2 or higher (except grade 3 peripheral neuropathy or
neutropaenia, as described below), a dose modification scheme
was implemented. Dose reduction was not required following the
first appearance of any grade 2 toxicity, although treatment was
interrupted/delayed until the toxicity had resolved to grades 0–1
and symptomatic treatment was initiated when possible. Treat-
ment with both agents was interrupted/delayed and the dose of
both agents was reduced by 25% in patients who experienced a
second occurrence of any grade 2 toxicity or at the first occurrence
of a grade 3 toxicity. If patients experienced a third occurrence of
any grade 2 toxicity or a second occurrence of any grade 3 toxicity,
treatment was interrupted/delayed until the toxicity resolved to
grades 0–1 and the dose of both agents was reduced by 50%.
Treatment with both agents was discontinued if, despite dose
reduction, any grade 2 toxicity occurred for a fourth time or any
grade 3 toxicity for a third time. Treatment was also discontinued
if patients experienced a grade 4 non-haematological toxicity.
Paclitaxel was discontinued and capecitabine treatment was
modified according to the scheme outlined above in patients
experiencing grade 3 peripheral neuropathy. Paclitaxel dose was
permanently reduced by 25% for patients who developed grade 4
neutropaenia for more than 5 days, or grade 3 or 4 neutropaenia
associated with a temperature of X381C. Paclitaxel was discon-
tinued if patients receiving the reduced dose experienced grade 4
or febrile neutropaenia. Patients with grade 4 thrombocytopaenia
were retreated with a 25% dose reduction after recovery. As
capecitabine was not expected to worsen or prolong neutropaenic
episodes, treatment with this agent could be continued during
episodes of grade 3–4 neutropaenia. However, capecitabine was
interrupted if any other grade 2 toxicity developed during the
neutropaenic episodes.
Assessment of compliance and dose intensity
Compliance to capecitabine treatment was monitored by ques-
tioning patients and counting their remaining pills at each
outpatient visit. The ratio of the actual administered dose to the
scheduled dose was calculated. Dose intensity was defined as the
total amount of drug given (mgm
 2) divided by the number of
weeks.
Pretreatment, follow-up studies and response evaluation
Prestudy screening assessments, completed within the 3 weeks
preceding treatment, included a full medical history, vital signs
and physical measurements, haematological and blood chemistry
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stests, electrocardiogram, chest X-ray, and computed tomography
(CT) scans.
Complete blood counts with differential counts were performed
every week to assess haematological toxicities, and physical
examinations and biochemical tests were performed before each
chemotherapy cycle. Response evaluation was performed by CT
scan every 2 cycles until disease progression or withdrawal from
study medication. Tumour response was classified on the basis of
the response evaluation criteria in solid tumours guidelines
(Therasse et al, 2000), with responses confirmed as lasting longer
than 4 weeks.
Statistical analysis
All enrolled patients were included in the intention-to-treat (ITT)
analysis of efficacy. This trial was designed using Simon’s two-
stage phase II designs (Simon, 1987). Assuming a target level of
interest, p1¼0.5, and a lower activity level, p0¼0.3, we planned to
enroll 19 patients initially. If seven or more responses were
observed, the trial would be continued. Accrual would be planned
to a total of 44 patients assuming a 10% dropout rate due to
protocol non-compliance. This design provides a probability
p0.05 of accepting drugs worse than p0 and a probability p0.20
of rejecting drugs better than p1.
Time to progression (TTP), survival and duration of response
were estimated as secondary end points by the Kaplan–Meier
method. The duration of response was defined as the interval from
the onset of complete response (CR) or partial response (PR) until
first appearance of evidence of progression. Time to progression
was calculated from the date of entry into the study until the date
of progression, and OS was measured from the date of entry to the
date of last follow-up or death.
RESULTS
Patient characteristics
A total of 45 patients were enrolled from June 2002 to May 2004,
and their baseline characteristics are shown in Table 1. Their
median age was 57 years, and 42 of 45 patients (93.3%) had a good
performance status (ECOG 0 or 1). Ten patients had recurrent
disease after previous curative gastrectomy and nine had previous
adjuvant chemotherapy (three FAM, five doxifluridine or 5-FU
plus cisplatin, and one doxifluridine plus mitomycin-C). The
median disease-free interval of relapsed patients was 33.0 months
(range¼16.4–55.6 months). Twenty-six patients (57.8%) had
multiple metastases involving two or more organs, with the
abdominal lymph nodes and liver being the most common sites of
metastases.
Efficacy and survival
A total of 43 patients were assessable for response (Table 2). Of the
two patients not assessable, one was lost to follow-up after the first
cycle of treatment, and the other died after the first cycle of
unknown cause, although brain metastasis was suspected. Of the
43 assessable patients, 2 achieved CR and 20 achieved PR, giving
an overall response rate of 48.9% (95% CI¼30.3–63.5%) in the
ITT population.
There was no difference in overall response rate between
patients who were pretreated and who were not with adjuvant
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Table 2 Antitumour activity
All patients
a (n¼45) History of previous adjuvant chemotherapy
Yes (n¼9) No (n¼36)
Response No. (%) No. (%) No. (%)
CR 2 4.4 1 11.1 1 2.8
PR 20 44.5 2 22.2 18 50.0
SD 15 33.3 6 66.7 9 25.0
PD 6 13.3 0 0 6 16.7
NA
b 2 4.4 0 0 2 5.6
aIntention-to-treat analysis.
bNot assessable.
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schemotherapy (33.3 vs 52.8%, P¼0.459 by Fisher’s exact test). The
median duration of response in the 22 responding patients was 6.1
months (range¼2.9–12.4 months). The median follow-up period
was 42.2 months (range¼31.2–54.3 months). The median TTP for
all patients was 5.6 months (95% CI¼3.9–7.2 months) (Figure 1),
and the median OS was 11.3 months (95% CI¼8.1–14.4 months)
(Figure 2), with a 1-year survival rate of 46.0% (95% CI¼31.4–
60.6%).
Poststudy treatment
After disease progression, 28 patients (62.2%). received second-
line chemotherapy, most commonly with irinotecan (21 patients;
75%) in combination with cisplatin/mitomycin-C or 5-FU/LV. Two
patients (7.1%) achieved PR and 5 (17.9%) had stable disease in
response to second-line chemotherapy, the median TTP was 1.5
months (95% CI¼1.3–1.8 months). Three patients (6.7%)
received palliative radiotherapy, and one patient underwent total
gastrectomy due to cancer bleeding.
Adverse events
A total of 248 treatment cycles (median¼6; range¼1–9 cycles)
were administered, with 246 cycles and 43 patients assessable for
safety. The frequencies of haematological and non-haematological
adverse events are shown in Tables 3 and 4, respectively. The most
common haematological adverse event was neutropaenia, which
occurred at grade 3 or 4 intensity in 20 patients (46.5%) and
during 51 cycles (20.7%). No patient experienced febrile neutro-
paenia. There were no treatment-related deaths.
Non-haematological adverse events included asthenia (100%),
alopecia (98%), neuropathy (93%), arthralgia (86%), nausea (74%),
hand–foot syndrome (72%), myalgia (67%), and constipation
(65%), but grade 3 or 4 non-haematological adverse events were
rare. Treatment was delayed or the dose was reduced during 34
cycles. Treatment was delayed during 5 cycles (2.0%) and in 5
patients (11.6%), due to neutropaenia (2 cycles), elevated
transaminase (2 cycles), and hand–foot syndrome (1 cycle).
Paclitaxel dose was reduced during 14 cycles (5.6%) in 4 patients
(9.3%), due to myalgia (8 cycles), arthralgia (4 cycles), neutropae-
nia (1 cycle) and neuropathy (1 cycle). The dose of capecitabine
was reduced during 25 cycles (10.1%) in 6 patients (14%), due to
hand–foot syndrome (17 cycles), and myalgia (8 cycles).
Ten patients (22.2%) withdrew from study treatment because of
financial problems or paclitaxel-induced neurotoxicity. These 10
patients received a median 3.5 cycles (range¼1–9 cycles) of
capecitabine monotherapy.
Over all treatment cycles, the mean dose intensity of paclitaxel
was 57.2mgm
 2 per week (range¼23.3–58.3mgm
 2 per week)
and that of capecitabine was 7277mgm
 2 per week
(range¼3080–7700mgm
 2 per week), corresponding to 98.0
and 94.5%, respectively of the planned dose intensities. The actual
dose intensity of both drugs was maintained at over 95% during
the first 5 chemotherapy cycles (Figure 3). There was 97.5%
compliance with capecitabine treatment during the first 6 cycles.
DISCUSSION
The results presented here suggest that the combination of
paclitaxel and capecitabine is effective and well tolerated as a
first-line regimen in patients with AGC. This combination regimen
demonstrated promising efficacy, with a tumour response rate of
48.9%, a median TTP of 5.6 months, and a median OS of 11.3
months. These results are comparable to other paclitaxel-based
combination regimens in patients with previously untreated AGC.
For example, in 29 evaluable patients treated with paclitaxel
175mgm
 2 on day 1 followed by 5-fluorouracil 1500mgm
 2 on
day 2 every 3 weeks, the response rate 65.5% and the median OS
was 12 months (Murad et al, 1999), and the combination of
paclitaxel with a 24-h continuous infusion of high-dose 5-FU/
folinic acid and cisplatin in 45 evaluable patients resulted in a 51%
response rate, a median TTP of 9 months, and a median OS of 14
months (Kollmannsberger et al, 2000).
The results of this combination of paclitaxel and capecitabine
(TX) seem to be also comparable in efficacy and even better in

































Figure 1 Time to progression for all patients.




























Figure 2 Overall survival for all patients.
Table 3 Haematological toxicity (by patients and cycles)
Grade (% of patients, n¼43)
a Grade (% of cycles, n¼246)
a
123 4 123 4
Anaemia 46.5 39.5 7.0 0 53.7 27.6 2.0 0
Leukopaenia 32.6 37.2 2.3 0 29.3 17.9 0.4 0
Neutropaenia
b 9.3 20.9 39.5 7.0 12.2 19.5 19.1 1.6
Thrombocytopaenia 7.0 0 0 0 3.3 0 0 0
aNCI CTC version 2.0.
bNo febrile neutropaenia or treatment-related death.
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ssafety as compared to the current standard platinum-containing
first-line regimens. In comparison with capecitabine plus cisplatin
(XP) or 5-FU plus cisplatin (FP) combination reported in a recent
phase III trial (Kang et al, 2006), this TX regimen was comparable
in terms of RR (48.9 vs 46/32%), TTP (5.6 months vs 5.6/5.0
months), and OS (11.3 months vs 10.5/9.3 months), and even better
in terms of risk of severe nausea/vomiting (0 vs 6/8%). Similarly, in
comparison to ECF of REAL-2 trial (Cunningham et al, 2006), in
addition to comparable efficacy, this TX regimen seems to be very
safe, especially in terms of infection risk. There was no febrile
neutropaenia and treatment-related death with TX regimen, while
there was 6.7–9.3% of febrile neutropaenia with ECF, ECX, EOF,
and EOX regimen in REAL-2 trial.
Two trials of paclitaxel/capecitabine combination in patients
with metastatic breast cancer (MBC) showed similar toxicities with
asthenia, alopecia, and hand–foot syndrome being common
(Batista et al, 2004; Gradishar et al, 2004). Although we found
that the incidence of grade 3 or 4 hand–foot syndrome and
neuropathy were similar in MBC and AGC patients, grade 3 or 4
neutropaenia was lower in MBC (12 and 15%) than in AGC (46.5%)
patients. This may have resulted from an underestimation in MBC
patients due to CBC evaluations every 3 weeks.
We found that the rate of nail toxicity (all grades) was 37.2% and
the rate of grade 3 hand–foot syndrome was 9.3%. In comparison,
the combination of docetaxel 75mgm
 2 i.v. on day 1 and
capecitabine 1250mgm
 2 p.o. twice daily on days 1–14 every 3
weeks resulted in rates of oncolysis (all grades) of 81% and of
grade 3 hand–foot syndrome of 50% (Park et al, 2004). These
differences may have resulted from the lower dose of capecitabine
in our regimen and from the use of docetaxel. Although it is
difficult to compare the incidence of neutropaenia, we observed no
incidence of febrile neutropaenia, whereas the previous trial
reported febrile neutropaenia in three patients (7%). These
findings suggest that the combination of paclitaxel and capecita-
bine may have a superior safety and tolerability profile than the
combination of docetaxel and capecitabine.
In previously untreated patients, single-agent docetaxel has demon-
strated response rates of 18, 20, and 24% when given at 100mgm
 2
(Sulkes et al, 1994; Einzig et al,1 9 9 6 ;M a v r o u d i set al,2 0 0 0 ) ,a n d
18% when given at 75mgm
 2 (Bang et al, 2002). Final results of a
randomised phase III trial in chemotherapy-naive patients with
locally advanced or metastatic gastric cancer showed that DCF
(docetaxel/cisplatin/5-FU) was superior to CF (cisplatin/5-FU) in
response rate (37 vs 25%), TTP (5.6 months vs 3.7 months) and OS
(9.2 months vs 8.6 months) (Van Cutsem et al, 2006). However, the
haematological toxicity in the DCF arm was significant, with grade 3
or 4 neutropaenia and febrile neutropaenia rates of 82.3 and 30.0%,
respectively, suggesting that the DCF regimen has questionable
clinical relevance as a standard regimen in patients with AGC.
The lower toxicities, very good compliance and higher dose
intensities demonstrated in the present study suggests that dose
escalation of capecitabine should be considered in AGC patients.
However, a recent retrospective analysis of the impact of dose
reduction in MBC patients treated with capecitabine suggests that
the dose of capecitabine can be reduced to minimise toxicity
without compromising efficacy (O’Shaughnessy and Blum, 2000).
In summary, we have shown that the combination of paclitaxel
and capecitabine is active and highly tolerable as first-line
chemotherapy for AGC. Response rates, TTP, and OS compare
favourably with previous studies of paclitaxel/5-FU. Replacing
infusional 5-FU with oral capecitabine improved convenience and
allowed treatment in an outpatient setting.
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